EU No-Deal Still Haunts UK Medtechs As Brexit Remains On A Knife Edge
Executive Summary
The UK is the middle of a week of Brexit votes in Parliament, but confusion for medtechs and the wider industrial community has not been quelled at all, regardless of two days of voting already, and a third to come today.
You may also be interested in...
EU No-Deal Scenario Looms Still, But MHRA’s Reg Oversight Of UK Medtech On Hold
UK parliament’s indecision over how – or if – to enact Brexit saw the planned March 29 withdrawal deadline come and go. The default positions of the inter-ministerial Office for Lifesciences (OLS) and health-care products regulator (MHRA) are still to prepare for a no-deal exit from the EU.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.